Dimensional Fund Advisors LP decreased its stake in shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) by 0.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 303,596 shares of the company’s stock after selling 100 shares during the period. Dimensional Fund Advisors LP owned approximately 0.45% of Diplomat Pharmacy worth $4,842,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in Diplomat Pharmacy by 73.1% in the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after buying an additional 3,056 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in Diplomat Pharmacy by 13.8% in the first quarter. BNP Paribas Arbitrage SA now owns 8,876 shares of the company’s stock valued at $142,000 after buying an additional 1,073 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in Diplomat Pharmacy during the first quarter valued at about $160,000. Mason Street Advisors LLC raised its stake in Diplomat Pharmacy by 8.4% in the first quarter. Mason Street Advisors LLC now owns 10,148 shares of the company’s stock valued at $162,000 after buying an additional 783 shares during the last quarter. Finally, Bank of Montreal Can raised its stake in Diplomat Pharmacy by 516.6% in the first quarter. Bank of Montreal Can now owns 11,260 shares of the company’s stock valued at $180,000 after buying an additional 9,434 shares during the last quarter. Institutional investors and hedge funds own 69.89% of the company’s stock.
Diplomat Pharmacy, Inc. (NYSE:DPLO) traded down 0.85% during mid-day trading on Monday, hitting $16.42. 53,299 shares of the stock were exchanged. Diplomat Pharmacy, Inc. has a 52 week low of $12.25 and a 52 week high of $33.00. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of 89.73 and a beta of 0.66. The company’s 50-day moving average price is $15.71 and its 200 day moving average price is $15.91.
Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Monday, August 7th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.27% and a return on equity of 7.97%. The business had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.14 billion. During the same period last year, the business earned $0.23 earnings per share. The business’s revenue for the quarter was up 3.5% on a year-over-year basis. Equities research analysts expect that Diplomat Pharmacy, Inc. will post $0.75 EPS for the current year.
Several analysts have issued reports on the stock. TheStreet upgraded shares of Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research report on Thursday, August 10th. Zacks Investment Research upgraded shares of Diplomat Pharmacy from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. BidaskClub lowered shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Cowen and Company increased their target price on shares of Diplomat Pharmacy from $12.00 to $17.00 and gave the stock a “market perform” rating in a report on Tuesday, May 9th. Finally, Leerink Swann reiterated a “market perform” rating and set a $18.00 target price (up from $16.00) on shares of Diplomat Pharmacy in a report on Wednesday, May 17th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the stock. Diplomat Pharmacy has a consensus rating of “Hold” and an average target price of $17.89.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
